Program
baricitinib
Also written as “Baricitinib”, “LY3009104” and “INCB028050”.
Its studies are mostly in Arthritis, Rheumatoid · Dermatitis, Atopic · Lupus Erythematosus, Systemic · COVID-19 · Arthritis, Juvenile, led by 5 companies.
Drug pageBaricitinib: every studyMany companies study it; this page follows only the 58 they lead. All 149 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 546 open or running | phase 4since Apr 12, 2019 | Aug 18, 2010 | Mar 2028phase 3 · NCT05723198 |
| Galvani Bioelectronics | 11 open or running | no phasesince Jul 5, 2021 | Jul 5, 2021 | Jul 2027NCT05003310 |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Aug 9, 2021 | Aug 9, 2021 | none ahead |
| Incepta Pharmaceuticalsits history only | 10 open or running | phase 3since Sep 20, 2021 | Sep 20, 2021 | none ahead |
| Incyteits history only | 10 open or running | phase 2since May 13, 2009 | May 13, 2009 | none ahead |
Also a collaborator on its studies: Q2 Solutions and Horus Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Galvani Bioelectronics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 5, 2021First study: no phase study in Arthritis, RheumatoidFirst studyNCT05003310 · 28 planned · United States, Netherlands
Ahead
- Jul 2027Primary completion: no phase study in Arthritis, RheumatoidNCT05003310
TargetBeta
“An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| momelotinibrule | GlaxoSmithKline | phase 3 | 17 |
Studies
The one study Galvani Bioelectronics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05003310Arthritis, Rheumatoid · United States, Netherlands | – | Recruiting | Jul 2027 | 28 |
How it is read
Names in the registry
- “Baricitinib”, 53 entries
- “LY3009104”, 5 entries
- “INCB028050”, 3 entries
- “Barcimiant”, 1 entry
- “Baricitinib suspension”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 13 studies
- Dermatitis, Atopic, 9 studies
- Lupus Erythematosus, Systemic, 4 studies
- COVID-19, 3 studies
- Arthritis, Juvenile, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.